Pieris Pharmaceuticals Inc (PIRS) Receives $10.00 Average Target Price from Brokerages

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has received an average rating of “Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

Several equities analysts recently commented on PIRS shares. BidaskClub cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday, November 11th. HC Wainwright set a $5.00 target price on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th.

Several hedge funds have recently made changes to their positions in PIRS. Public Employees Retirement System of Ohio acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $110,000. Marshall Wace LLP acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $118,000. California Public Employees Retirement System acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $179,000. Alpine Global Management LLC raised its stake in shares of Pieris Pharmaceuticals by 125.0% in the 2nd quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 25,000 shares in the last quarter. Finally, DRW Securities LLC raised its stake in shares of Pieris Pharmaceuticals by 50.0% in the 2nd quarter. DRW Securities LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 15,000 shares in the last quarter. Institutional investors own 65.36% of the company’s stock.

NASDAQ:PIRS opened at $2.84 on Friday. The firm has a market cap of $149.45 million, a P/E ratio of -7.28 and a beta of 1.98. Pieris Pharmaceuticals has a one year low of $2.39 and a one year high of $9.75.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The firm had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.16 million. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. Equities analysts predict that Pieris Pharmaceuticals will post -0.45 earnings per share for the current year.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Further Reading: How interest rates affect municipal bond prices

Analyst Recommendations for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply